Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells independently of cyclooxygenase

Annals of the New York Academy of Sciences

Volumn 1171, Issue , 2009, Pages 635-641

  Kim, Su Hyeon ^a   Kim, Su Hyeong ^a   Song, Yoo Choel ^a   Song, Yong Sang ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Celecoxib; Cisplatin; Cyclooxygenase; Vulvar cancer

Indexed keywords

CELECOXIB; CISPLATIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PIROXICAM; PROSTAGLANDIN E2;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL ASSAY; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; VULVA CANCER;

EID: 69149093391     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04888.x     Document Type: Conference Paper

References (24)

1. Kalter, E. G. Weissmann. 1997. Steroids, aspirin, and inflammation. Inflammation 2 : 295 307.
2. Vane, J.R., Y.S. Bakhle R.M. Botting. 1998. Cyclooxygenase 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38 : 97 120.
3. Williams, C.S., M. Mann R.N. DuBois. 1999. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18 : 7908 7916.
4. Cao, Y. S.M. Prescott. 2002. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J. Cell. Physiol. 190 : 279 286.
5. Singh, G. G. Triadafilopoulos. 1999. Epidemiology of NSAID induced gastrointestinal complications. J. Rheumatol. Suppl. 56 : 18 24.
6. Wolfe, M.M., D.R. Lichtenstein G. Singh. 1999. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 340 : 1888 1899.
7. Lewis, J.D. et al. 2005. Risk of serious upper gastrointestinal toxicity with over-the-counter nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 129 : 1865 1874.
8. Hawkey, C.J. 2005. COX-2 chronology. Gut 54 : 1509 1514.
9. Zhao, S.Z. et al. 2001. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organisation/Uppsala Monitoring Centre safety database. Clin. Ther. 23 : 1478 1491.
10. Koki, A.T. J.L. Masferrer. 2002. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 9 : 28 35.
11. Dandekar, D.S. et al. 2005. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int. J. Cancer 115 : 484 492.
12. Lin, J. et al. 2005. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem. Pharmacol. 70 : 658 667.
13. Shaik, M.S. et al. 2006. Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int. J. Cancer 118 : 396 404.
14. Lee, T.S. et al. 2007. Increased cyclooxygenase-2 expression associated with inflammatory cellular infiltration in elderly patients with vulvar cancer. Ann. N. Y. Acad. Sci. 1095 : 143 153.
15. Kim, S.H. et al. 2004. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kB as a possible target. J. Cancer Res. Clin. Oncol. 130 : 551 560.
16. Bijman, M.N. et al. 2008. Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. Biochem. Pharmacol. 75 : 427 437.
17. Song, X. et al. 2002. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J. Natl. Cancer Inst. 94 : 585 591.
18. Waskewich, C. et al. 2002. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. 62 : 2029 2033.
19. Lin, J. et al. 2005. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem. Pharmacol. 70 : 658 667.
20. Pyrko, P. et al. 2006. Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2- inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol. Cancer 5 : 19.
21. Schonthal, A.H. 2006. Anti-tumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2. Neurosurg. Focus. 20 : 1 10.
22. Liu, B. et al. 2007. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Cell Biol. Int. : In press.
23. Hashitani, S. et al. 2003. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int. J. Oncol. 23 : 665 672.
24. Monick, M.M. et al. 2002. Hunninghake GW. Phosphatidylinositol 3-Kinase activity negatively regulates stability of cyclooxygenase 2 mRNA. J. Biol. Chem. 277 : 23992 23000.